RESEARCH AND DEVELOPMENT AT ALK

Pioneering allergy research

Under­standing allergy

ALK has an unrivalled understanding of allergens and how they affect the human body, as well as the link between allergy and respiratory diseases such as asthma.

understanding_allergy

News

  • Post date
    08/16/2017
    Six-month interim report (Q2) 2017
  • Post date
    08/08/2017
    Release date of six-month interim report (Q2) 2017 and audio cast
  • Post date
    07/31/2017
    Management change at ALK
  • Post date
    07/07/2017
    Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children
  • Post date
    06/20/2017
    ALK symposium reveals early treatment is critical for respiratory allergic disease in children and adolescents
  • Post date
    05/09/2017
    Three-month interim report (Q1) 2017
  • Post date
    05/04/2017
    ALK's HDM SLIT-tablet, ACARIZAX®, approved in Canada
  • Post date
    05/03/2017
    Release date of three-month interim report (Q1) 2017 and audio cast
  • Post date
    04/16/2017
    ACARIZAX® approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis
Prevention of asthma symptoms
ALK is leading the industry’s research into the role respiratory allergies play in asthma. As part of this research, we conducted the world’s largest allergy immunotherapy trial ever carried out in children to investigate the effect of a new treatment on the risk of developing asthma.
The link between allergic rhinitis and allergic asthma
Respiratory allergens, such as house dust mites, can cause the airways to inflame. In time, this can lead to asthma, or the worsening of symptoms in people who are already asthmatic. A new treatment option can treat both house dust mite allergic rhinitis and allergic asthma.

ALK in brief

ALK at a glance
ALK is a research-driven, global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. We are the foremost innovators in allergy immunotherapy – a unique treatment which reduces allergic symptoms and treats the cause of the allergy.
Global presence
ALK employs around 2,300 employees worldwide and has affiliates, production facilities and distributors around the globe. Today, around 1.5 million people worldwide use our products.
ALK's pipeline
Our development programme covers the four most important outdoor allergens in Europe, the USA and Japan (grass, birch and related trees, ragweed and Japanese cedar) and the most important indoor allergen in the world (house dust mites).
ALK's history
ALK has been at the forefront of allergy treatment for almost a century. Our story can be traced back to a small laboratory in Copenhagen, Denmark, in 1923.